Halozyme To Participate In 2020 Wells Fargo Virtual Healthcare Conference
Halozyme Therapeutics (NASDAQ: HALO) CEO Dr. Helen Torley will speak at the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 10:00 a.m. ET. Interested participants can access a live webcast through the "Investors" section of Halozyme's website, with an archive available for 90 days post-event. Halozyme specializes in biopharmaceutical solutions, particularly through its ENHANZE® technology that streamlines drug delivery, benefiting over 400,000 patients globally. The company partners with leading firms to enhance treatment efficiency and patient experiences.
- None.
- None.
SAN DIEGO, Sept. 2, 2020 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Dr. Helen Torley, president and chief executive officer, will participate in the upcoming 2020 Wells Fargo Virtual Healthcare Conference. Dr. Torley will take part in a fireside chat at 10:00 a.m. ET / 07:00 a.m. PT on Wednesday, September 9, 2020.
A live webcast of the event can be accessed through the "Investors" section of Halozyme's website (www.halozyme.com), and an archive will be made available for 90 days following the event. To access a live webcast, please visit Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.
About Halozyme
Halozyme is a biopharmaceutical company bringing disruptive solutions to significantly improve patient experiences and outcomes for emerging and established therapies. Halozyme advises and supports its biopharmaceutical partners in key aspects of new drug development with the goal of improving patients' lives while helping its partners achieve global commercial success. As the innovators of the ENHANZE® technology, which can reduce hours-long treatments to a matter of minutes, Halozyme's commercially-validated solution has positively impacted more than 400,000 patient lives via five commercialized products across more than 100 global markets. Halozyme and its world-class partners are currently advancing multiple therapeutic programs intended to deliver innovative therapies, with the potential to improve the lives of patients around the globe. Halozyme's proprietary recombinant human hyaluronidase enzyme rHuPH20 forms the basis of the ENHANZE® drug delivery technology and is used to facilitate the subcutaneous delivery of injected drugs and fluids, potentially reducing the treatment burden of other drugs to patients. Halozyme has licensed its ENHANZE® drug delivery technology to leading pharmaceutical and biotechnology companies including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly, Bristol-Myers Squibb, Alexion and argenx. Halozyme derives revenues from these collaborations in the form of milestones and royalties as the Company's partners make progress developing and commercializing their products being developed with ENHANZE®. Halozyme is headquartered in San Diego. For more information visit www.halozyme.com.
Contact:
Al Kildani
Vice President, Investor Relations and Corporate Communications
858-704-8122
ir@halozyme.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/halozyme-to-participate-in-2020-wells-fargo-virtual-healthcare-conference-301123227.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme participate in the 2020 Wells Fargo Virtual Healthcare Conference?
How can I access the Halozyme conference webcast?
What is Halozyme's ENHANZE® technology?
How many patients have benefited from Halozyme's solutions?
Which companies partner with Halozyme for drug development?
